Insta
Bharat Biotech And Serum Institute To Soon Begin Late-Stage Clinical Trials Of Intranasal COVID-19 Vaccines
Swarajya Staff
Oct 19, 2020, 10:13 AM | Updated 10:13 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
In a positive development, the Pune based Serum Institute of India (SII) and Hyderabad based Bharat Biotech are expected to begin the last stage clinical trials of intranasal COVID-19 vaccines in the coming months, reports Economic Times.
Intranasal vaccination trials gain significance as the possible vaccines which are presently undergoing trials are all administered by injection as per the World Health Organisation (WHO).
The development was shared by Union Health Minister Dr Harsh Vardhan, who also shared that the late-stage trials can involve as many as 30,000-40,000 participants.
Meanwhile, the Government has also given its go-ahead for the late-stage clinical trials of the Russian Sputnik-V COVID-19 vaccine to be conducted in India. The vaccine has been developed by the Russian Direct Investment Fund (RDIF) and its trials will be conducted in India by pharmaceutical sector behemoth Dr Reddy's Laboratories Limited.
The development of multiple vaccines and trials of the same is advancing at a rapid pace across the world.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.